Visual Literacy

A site with different ways of presenting information in a visual way that is more comprehensive than the standard bar, pie charts, and tables. The Periodic Table of Visualization Methods shows over one-hundred different examples. The page provides great interactive resources to better explain the concepts featured

Heavy metals induced morphometrical alterations in earthworms granulocytes

none5Calisi A.; Pagliara P.; Leomanni A.; Lionetto M.G.; Schettino T.Calisi, Antonio; Pagliara, Patrizia; Leomanni, Alessandro; Lionetto, Maria Giulia; Schettino, Trifon

Experimental Validation of a Novel Method for Harmonic Mitigation for a Three-Phase Five-Level Cascaded H-Bridges Inverter

In modern high-power electrical drives, the efficiency of the system is a crucial constraint. Moreover, the efficiency of power converters plays a fundamental role in modern applications requiring also a limited weight, such as the electric vehicles and novel more electric aircraft. The reduction of losses pushes for systems with a dc bus and a high number of dc/ac converters, widespread in the vehicle, not burdened by a too expensive data processing system. The purpose of this article is to concur to reduce losses by proposing an innovative selective harmonic mitigation method based on the identification of the working areas where the reference harmonics present lower amplitudes. In particular, the main objective is to find a new way to calculate the control angles in real-time operation without solving nonlinear equations, whose resolution would require expensive controllers. Through a very simple approach, the polynomial equations, which drive the control angles, were detected for a three-phase five-level cascaded H-bridge inverter and implemented in a digital system to real-time operation with a low computational cost. As a result, a comparison between the simulation and experimental behavior is presented. In the last part of this article, a real electric machine is driven by considering the appropriate working areas and current harmonics are also evaluated

Glossario Digitale e Tecnologie | ICOM Italia | Commissione Tecnologie Digitali per il Patrimonio Culturale

Le tecnologie sono strumenti fondamentali per le attività del museo. La Commissione Tecnologie Digitali per il Patrimonio Culturale di ICOM Italia si occupa di analizzare e stimolare il dialogo sugli aspetti del digitale in ambito museale. Questo glossario ha lo scopo di raccogliere, in forma divulgativa, le definizioni delle tecnologie e dei termini di riferimento che riguardano digitale e museo. Le definizioni sono pensate per essere di supporto ai curatori, ai progettisti e ai direttori dei musei nella scelta delle tecnologie più adatte per il proprio contesto di riferimento e si pone come un piccolo supporto terminologico. Le voci sono la sintesi di consultazione di fonti riconosciute e di esperienza personale maturata dai componenti del gruppo di lavoro. Data la continua evoluzione tecnologica il lavoro si presenta in fieri ed in continuo aggiornamento, periodicamente il glossario verrà aggiornato, integrato ed ampliato con nuove definizioni

Dysphagia in amyotrophic lateral sclerosis: prevalence and clinical findings.

Objectives: To characterize swallowing deficits in amyotrophic lateral sclerosis (ALS); investigate the delay in dysphagia onset; estimate correlations between dysphagia severity and patients' functional status; identify the symptom(s) most likely to predict dysphagia. Materials and methods: A group of 49 consecutive patients with ALS, 14 with bulbar onset and 35 with spinal onset, underwent swallowing evaluation including bedside and fiberoptic endoscopic examination to detect dysphagia. Results: Patients with dysphagia were more likely than those without to have bulbar onset ALS (P = 0.02); more severely impaired chewing (P = 0.01); and tongue muscle deficits (P = 0.001). The only variable measured at first examination significantly associated with dysphagia was a more than mild tongue muscle deficit. The only variable useful in predicting dysphagia was a chewing deficit. In 10 of the 49 patients studied, swallowing evaluation disclosed an impaired cough reflex. Conclusions: Dysphagia in patients with ALS correlates significantly with bulbar onset and with oral swallowing impairment. Fiberoptic swallowing evaluation is a useful tool for detecting swallowing deficits and laryngeal sensitivity in patients with ALS. An impaired cough reflex is an unexpected finding in many patients with ALS. © 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd

Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

BackgroundTocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients.MethodsA multicenter, single-arm, hypothesis-driven trial was planned, according to a phase 2 design, to study the effect of tocilizumab on lethality rates at 14 and 30 days (co-primary endpoints, a priori expected rates being 20 and 35%, respectively). A further prospective cohort of patients, consecutively enrolled after the first cohort was accomplished, was used as a secondary validation dataset. The two cohorts were evaluated jointly in an exploratory multivariable logistic regression model to assess prognostic variables on survival.ResultsIn the primary intention-to-treat (ITT) phase 2 population, 180/301 (59.8%) subjects received tocilizumab, and 67 deaths were observed overall. Lethality rates were equal to 18.4% (97.5% CI: 13.6-24.0, P=0.52) and 22.4% (97.5% CI: 17.2-28.3, P<0.001) at 14 and 30 days, respectively. Lethality rates were lower in the validation dataset, that included 920 patients. No signal of specific drug toxicity was reported. In the exploratory multivariable logistic regression analysis, older age and lower PaO2/FiO2 ratio negatively affected survival, while the concurrent use of steroids was associated with greater survival. A statistically significant interaction was found between tocilizumab and respiratory support, suggesting that tocilizumab might be more effective in patients not requiring mechanical respiratory support at baseline.ConclusionsTocilizumab reduced lethality rate at 30 days compared with null hypothesis, without significant toxicity. Possibly, this effect could be limited to patients not requiring mechanical respiratory support at baseline.Registration EudraCT (2020-001110-38); clinicaltrials.gov (NCT04317092)

Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

BackgroundTocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients.MethodsA multicenter, single-arm, hypothesis-driven trial was planned, according to a phase 2 design, to study the effect of tocilizumab on lethality rates at 14 and 30 days (co-primary endpoints, a priori expected rates being 20 and 35%, respectively). A further prospective cohort of patients, consecutively enrolled after the first cohort was accomplished, was used as a secondary validation dataset. The two cohorts were evaluated jointly in an exploratory multivariable logistic regression model to assess prognostic variables on survival.ResultsIn the primary intention-to-treat (ITT) phase 2 population, 180/301 (59.8%) subjects received tocilizumab, and 67 deaths were observed overall. Lethality rates were equal to 18.4% (97.5% CI: 13.6-24.0, P=0.52) and 22.4% (97.5% CI: 17.2-28.3, P<0.001) at 14 and 30 days, respectively. Lethality rates were lower in the validation dataset, that included 920 patients. No signal of specific drug toxicity was reported. In the exploratory multivariable logistic regression analysis, older age and lower PaO2/FiO2 ratio negatively affected survival, while the concurrent use of steroids was associated with greater survival. A statistically significant interaction was found between tocilizumab and respiratory support, suggesting that tocilizumab might be more effective in patients not requiring mechanical respiratory support at baseline.ConclusionsTocilizumab reduced lethality rate at 30 days compared with null hypothesis, without significant toxicity. Possibly, this effect could be limited to patients not requiring mechanical respiratory support at baseline.Registration EudraCT (2020-001110-38); clinicaltrials.gov (NCT04317092)